Abstract
BackgroundAnti-programmed cell death protein 1 (PD-1) antibodies are now routinely administered for metastatic melanoma and for increasing numbers of other cancers, but still only a fraction of patients respond. Better...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have